MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Biognosys and Thermo Fisher Sign Reselling Agreement for Spectronaut Proteomics Software

NextEdge Admin

19 Sep 2024

2 min 11 sec

Biognosys has announced a reselling agreement with Thermo Fisher Scientific for its Spectronaut proteomics software. As part of the partnership, the two companies will comarket and sell Spectronaut, which is specifically designed for data-independent acquisition (DIA) proteomics experiments.

The agreement grants Thermo Fisher the right to quote and sell Spectronaut directly from its product catalog. This enables customers to purchase both a Thermo Fisher mass spectrometry system and the Spectronaut software as part of a single, streamlined package.

Although financial details of the agreement were not disclosed, the collaboration is expected to enhance accessibility to Spectronaut for users of Thermo Fisher’s mass spectrometry instruments. Oliver Rinner, CEO and founder of Biognosys, emphasized the importance of data analysis in mass spectrometry-based proteomics, noting that the partnership will help advance the DIA acquisition method, a cutting-edge approach in discovery proteomics. He also highlighted the value of cross-platform comparability in accelerating progress in the emerging field of proteomics.

August Specht, Vice President of R&D for chromatography and mass spectrometry at Thermo Fisher, echoed these sentiments. He expressed enthusiasm for the collaboration, stating that combining Spectronaut with Thermo Fisher’s mass spectrometry systems will offer researchers a powerful, integrated solution for DIA proteomics workflows.

This partnership is expected to provide a comprehensive solution for researchers, facilitating more efficient proteomics research across different platforms.